CIBINQO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cibinqo, and when can generic versions of Cibinqo launch?
Cibinqo is a drug marketed by Pfizer and is included in one NDA. There are three patents protecting this drug.
This drug has sixty-five patent family members in forty-four countries.
The generic ingredient in CIBINQO is abrocitinib. Two suppliers are listed for this compound. Additional details are available on the abrocitinib profile page.
DrugPatentWatch® Generic Entry Outlook for Cibinqo
Cibinqo will be eligible for patent challenges on January 14, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 19, 2034. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for CIBINQO
International Patents: | 65 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 39 |
Clinical Trials: | 2 |
Patent Applications: | 38 |
Drug Prices: | Drug price information for CIBINQO |
What excipients (inactive ingredients) are in CIBINQO? | CIBINQO excipients list |
DailyMed Link: | CIBINQO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CIBINQO
Generic Entry Date for CIBINQO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for CIBINQO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Pfizer | Phase 2 |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
Innovaderm Research Inc. | Phase 4 |
Pharmacology for CIBINQO
Drug Class | Janus Kinase Inhibitor |
Mechanism of Action | Janus Kinase Inhibitors P-Glycoprotein Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for CIBINQO
US Patents and Regulatory Information for CIBINQO
CIBINQO is protected by three US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of CIBINQO is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting CIBINQO
Pyrrolo[2,3-D]pyrimidine derivatives
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Pyrrolo[2,3-D]pyrimidine derivatives
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Pyrrolo[2,3-D]pyrimidine derivatives
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF ADULTS WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS OR WHEN USE OF THOSE THERAPIES IS INADVISABLE
FDA Regulatory Exclusivity protecting CIBINQO
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
NEW PATIENT POPULATION
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | CIBINQO | abrocitinib | TABLET;ORAL | 213871-001 | Jan 14, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | CIBINQO | abrocitinib | TABLET;ORAL | 213871-002 | Jan 14, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Pfizer | CIBINQO | abrocitinib | TABLET;ORAL | 213871-001 | Jan 14, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | CIBINQO | abrocitinib | TABLET;ORAL | 213871-003 | Jan 14, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Pfizer | CIBINQO | abrocitinib | TABLET;ORAL | 213871-002 | Jan 14, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Pfizer | CIBINQO | abrocitinib | TABLET;ORAL | 213871-003 | Jan 14, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for CIBINQO
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pfizer Europe MA EEIG | Cibinqo | abrocitinib | EMEA/H/C/005452 Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. |
Authorised | no | no | no | 2021-12-09 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for CIBINQO
When does loss-of-exclusivity occur for CIBINQO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 4857
Estimated Expiration: ⤷ Try a Trial
Australia
Patent: 14220357
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2015019634
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 00703
Estimated Expiration: ⤷ Try a Trial
Chile
Patent: 15002303
Estimated Expiration: ⤷ Try a Trial
China
Patent: 5008362
Estimated Expiration: ⤷ Try a Trial
Patent: 7089985
Estimated Expiration: ⤷ Try a Trial
Costa Rica
Patent: 150395
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0171599
Estimated Expiration: ⤷ Try a Trial
Patent: 0190152
Estimated Expiration: ⤷ Try a Trial
Cuba
Patent: 275
Estimated Expiration: ⤷ Try a Trial
Patent: 150078
Estimated Expiration: ⤷ Try a Trial
Cyprus
Patent: 19502
Estimated Expiration: ⤷ Try a Trial
Patent: 21468
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 58921
Estimated Expiration: ⤷ Try a Trial
Patent: 90421
Estimated Expiration: ⤷ Try a Trial
Dominican Republic
Patent: 015000206
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 7879
Estimated Expiration: ⤷ Try a Trial
Patent: 1591255
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 58921
Estimated Expiration: ⤷ Try a Trial
Patent: 90421
Estimated Expiration: ⤷ Try a Trial
Georgia, Republic of
Patent: 01606600
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 13881
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 37192
Estimated Expiration: ⤷ Try a Trial
Patent: 41778
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 0132
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 45179
Estimated Expiration: ⤷ Try a Trial
Patent: 16509049
Estimated Expiration: ⤷ Try a Trial
Patent: 17165762
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 2022502
Estimated Expiration: ⤷ Try a Trial
Patent: 58921
Estimated Expiration: ⤷ Try a Trial
Patent: 90421
Estimated Expiration: ⤷ Try a Trial
Malaysia
Patent: 7476
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 15010928
Estimated Expiration: ⤷ Try a Trial
Moldova, Republic of
Patent: 35
Estimated Expiration: ⤷ Try a Trial
Patent: 150073
Estimated Expiration: ⤷ Try a Trial
Montenegro
Patent: 904
Estimated Expiration: ⤷ Try a Trial
Patent: 301
Estimated Expiration: ⤷ Try a Trial
Morocco
Patent: 347
Estimated Expiration: ⤷ Try a Trial
Netherlands
Patent: 1155
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 0411
Estimated Expiration: ⤷ Try a Trial
Norway
Patent: 52752
Estimated Expiration: ⤷ Try a Trial
Peru
Patent: 151764
Estimated Expiration: ⤷ Try a Trial
Philippines
Patent: 015501779
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 58921
Estimated Expiration: ⤷ Try a Trial
Patent: 90421
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 58921
Estimated Expiration: ⤷ Try a Trial
Patent: 90421
Estimated Expiration: ⤷ Try a Trial
Serbia
Patent: 503
Estimated Expiration: ⤷ Try a Trial
Patent: 245
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 201505816U
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 58921
Estimated Expiration: ⤷ Try a Trial
Patent: 90421
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 1505454
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1787858
Estimated Expiration: ⤷ Try a Trial
Patent: 150109434
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 47525
Estimated Expiration: ⤷ Try a Trial
Patent: 13052
Estimated Expiration: ⤷ Try a Trial
Taiwan
Patent: 07408
Estimated Expiration: ⤷ Try a Trial
Patent: 1443055
Estimated Expiration: ⤷ Try a Trial
Tunisia
Patent: 15000355
Estimated Expiration: ⤷ Try a Trial
Turkey
Patent: 1902525
Estimated Expiration: ⤷ Try a Trial
Ukraine
Patent: 1804
Estimated Expiration: ⤷ Try a Trial
Uruguay
Patent: 337
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering CIBINQO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hungary | E041778 | ⤷ Try a Trial | |
China | 107089985 | 作为詹纳斯相关激酶(JAK)抑制剂的吡咯并[2,3‑D]嘧啶衍生物 (Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (JAK)) | ⤷ Try a Trial |
Tunisia | 2015000355 | DERIVES DE PYRROLO [2, 3-D] PYRIMIDINE SERVANT D'INHIBITEURS DE KINASES DE TYPE JANUS (JAK) | ⤷ Try a Trial |
Japan | 6145179 | ⤷ Try a Trial | |
Dominican Republic | P2015000206 | DERIVADOS DE PIRROLO[2,3-D]PIRIMIDINA COMO INHIBIDORES DE QUINASAS JANUS (JAK) | ⤷ Try a Trial |
Portugal | 3290421 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CIBINQO
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2958921 | CA 2022 00003 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ABROCITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1593 20211210 |
2958921 | 301155 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ABROCITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: PLGB 00057/1703-1705 20210908 |
2958921 | LUC00261 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ABROCITINIB, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1593 20211210 |
2958921 | PA2022502 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: ABROCITINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/21/1593 20211209 |
2958921 | 2022C/505 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ABROCITINIB, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1593 20211210 |
2958921 | 122022000007 | Germany | ⤷ Try a Trial | PRODUCT NAME: ABROCITINIB, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1593 20211209 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |